Transport properties of Andreev polarons in superconductor-semiconductor-superconductor junction with superlattice structure

Transport properties of a superconductor-semiconductor-superconductor (S-Sm-S) junction with superlattice structure are investigated. Differential resistance as a function of voltage shows oscillatory behavior under the irradiation of radio-frequency (RF) waves with the specific frequency of 1.77 GHz regardless of the superconducting materials and the junction lengths. Experimental data are quantitatively explained in terms of the coupling of superconducting quasiparticles with long-wavelength acoustic phonons indirectly excited by the RF waves. We propose that the strong coupling causes the formation of novel composite particles, Andreev polarons.Comment: 4 pages, 4 figure

Bose-Einstein Condensation of Europium

We report the realization of a Bose-Einstein condensate of europium atoms, which is a strongly dipolar species with unique properties, a highly symmetric $[\mathrm{Xe}]\ 4f^7 6s^2\ {}^8\mathrm{S}_{7/2}$ electronic ground state and a hyperfine structure. By means of evaporative cooling in a crossed optical dipole trap, we produced a condensate of ${}^{151}$Eu containing up to $5\times 10^4$ atoms. The scattering length of ${}^{151}$Eu was estimated to be $a_s = 110(4)\, a_\mathrm{B}$ by comparing the velocities of expansion of condensates with different orientations of the atomic magnetic moments. We observed deformation of the condensate in the vicinity of the Feshbach resonance at $1.32\,\mathrm{G}$ with a width of $10\,\mathrm{mG}$.Comment: 5 pages, 4 figure

Induction of inverted morphology in brain organoids by vertical-mixing bioreactors

上下動撹拌培養装置を用いた流体制御により誘導した反転型脳オルガノイド 脳オルガノイド誘導の流体シミュレーションと流体力学的理解. 京都大学プレスリリース. 2021-10-27.How you mix cells changes the brain. 京都大学プレスリリース. 2021-10-28.Organoid technology provides an opportunity to generate brain-like structures by recapitulating developmental steps in the manner of self-organization. Here we examined the vertical-mixing effect on brain organoid structures using bioreactors and established inverted brain organoids. The organoids generated by vertical mixing showed neurons that migrated from the outer periphery to the inner core of organoids, in contrast to orbital mixing. Computational analysis of flow dynamics clarified that, by comparison with orbital mixing, vertical mixing maintained the high turbulent energy around organoids, and continuously kept inter-organoid distances by dispersing and adding uniform rheological force on organoids. To uncover the mechanisms of the inverted structure, we investigated the direction of primary cilia, a cellular mechanosensor. Primary cilia of neural progenitors by vertical mixing were aligned in a multidirectional manner, and those by orbital mixing in a bidirectional manner. Single-cell RNA sequencing revealed that neurons of inverted brain organoids presented a GABAergic character of the ventral forebrain. These results suggest that controlling fluid dynamics by biomechanical engineering can direct stem cell differentiation of brain organoids, and that inverted brain organoids will be applicable for studying human brain development and disorders in the future

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post-treatment serum soluble PD-L1 (sPD-L1) has been identified as a potential biomarker for assessing ICI efficacy through fixed-point observations. However, existing studies on sPD-L1 changes have produced inconsistent results or have had sample sizes too small to detect clinically meaningful effect sizes. To elucidate the role of sPD-L1, we conducted a collaborative individual patient data meta-analysis of PD-1 inhibitor treatments.MethodsWe conducted a thorough search of articles in PubMed via Medline, Embase, Scopus, and Cochrane databases from inception to October 20, 2023. Trials were deemed eligible if they contained individual datasets for advanced NSCLC patients, including data on overall survival (OS)/progression-free survival (PFS), as well as pre- and post-treatment sPD-L1 levels after 3-4 cycles of PD-1 inhibitor treatments. Our analysis focused on patients who completed 3-4 cycles of PD-1 inhibitor treatments. The primary outcome measure was OS/PFS, and we assessed changes in sPD-L1 concentration pre- and post-treatment through ELISA analyses.ResultsFrom our search, we identified a potential seven trials, encompassing 256 patients. Among these, two trials with 26 patients met the criteria for inclusion in our primary analyses. Over a median follow-up period of 10 months, pooled univariate analysis revealed that increases in sPD-L1 levels during PD-1 inhibitor treatment were not associated with OS (HR = 1.25; CI: 0.52–3.02)/PFS (HR = 1.42; CI: 0.61–3.30) when compared to cases with sPD-L1 decreases. Subgroup analyses indicated that the impact of sPD-L1 changes on overall mortality/progression-related mortality remained consistent regardless of gender, age, or the type of treatment (nivolumab or pembrolizumab).ConclusionOur findings suggest that changes in sPD-L1 levels during PD-1 inhibitor treatment do not significantly influence the prognosis of advanced NSCLC patients, regardless of gender, age, or treatment type. Continuous monitoring of sPD-L1 may not offer significant advantages compared to fixed-point observations